Eledon Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eledon Pharmaceuticals, Inc. (ELDN)
CIK: 0001404281
Period of Report: 2021-06-09

Reporting Person: Gros David-Alexandre C (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-09	Common Stock	P	3000	$8.01	Acquired	3000	Direct

Footnotes

F1: This Form 4 reports an open market purchase by the Reporting Person of shares of common stock in accordance with the Issuer's trading policies.